ClinicalTrials.gg
RecruitingNCT03723473SPECTROAOMIUpdated Apr 25, 2024

Spectroscopy in Functional Assessment of Peripheral Artery Disease (spectroAMI)

An observational study in Arterial Occlusive Diseases, sponsored by Centre Hospitalier Universitaire de Saint Etienne. Recruiting at 1 site in France. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-04-25.

Sponsored by Centre Hospitalier Universitaire de Saint Etienne · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 7 months ago, but the record still lists the study as recruiting.
  • Started Feb 2019; still recruiting 7 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
40
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Arterial Occlusive Diseases with a site in France — 4 open to participants now, 5 under way, none of them phase 3. Arterial Occlusive Diseases · France.

Started
2019
the only one that year
Observational
6 of 15
1 open now
Registered
6th of 15
by date
Lead sponsor
2 of 15
Centre Hospitalier Universitaire de Saint Etienne

Among the 15 studies in Arterial Occlusive Diseases with a site in France, this one is the only one that started in 2019, is one of 6 observational ones, and was the 6th registered.

Arterial Occlusive Diseases

230 studies on the registry are indexed under Arterial Occlusive Diseases; 27 are open to participants now.

Browse Arterial Occlusive Diseases studies →

Open to participants now

4 of the 15 studies in Arterial Occlusive Diseases with a site in France are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 20 Arterial Occlusive Diseases studies recruiting now, 13 (65%) set no upper age limit and 2 (10%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Arterial Occlusive Diseases with a site in France, or all of them as a file.
02

Study summary

To explore the reliability of P-31 MR spectroscopy mitochondrial function in patients with peripheral arterial occlusive disease.

Read the detailed description

Peripheral arterial occlusive disease (PAOD) is defined as the partial or total obstruction of one or more lower extremity arteries, most often of atherosclerotic origin. It is a common disease whose 5-years mortality is near 30%.The positive diagnosis is based on clinical examination and measurement of the ankle-brachial index (ABI), which is the ratio of systolic pressure of ankle and brachial systolic pressure. The threshold value for the diagnosis is \<0.90. Physiopathologically, mitochondria have the predominant role of providing the ATP necessary for the energetic needs of myocytes, which increase drastically during muscle contraction during exercise. This energy production is of course conditioned by the availability of oxygen. In patients with PAOD, the decrease in blood flow secondary to significant stenosis has the direct consequence of disrupting oxygen delivery to distal muscles and thus limiting muscular performance. Because mitochondrial respiration is the only metabolic pathway capable of providing the energy needed to sustain an effort of several minutes, intermittent claudication in PAOD has logically been related to a hemodynamic mechanism of intermittent muscle hypoperfusion. Recently, an increasing number of histological or functional studies have suggested that episodes of ischemia-reperfusion could induce mitochondrial dysfunction. Medical treatment of patients frequently includes statins while a direct deleterious effect on mitochondrial function has been suspected, inducing a deterioration of the muscular oxidative capacity which would increase the factors hemodynamics and may accumulate in mitochondrial myopathy. In the light of these elements, it is clear that there would be a benefit in being able to distinguish and quantify 1) the part of the reduction of mitochondrial activity secondary to the hemodynamic factor alone due to a decreased muscle perfusion 2) the mitochondrial involvement (mitochondriopathy) potentially induced by oxidative stress in PAOD. 2 sub-groups are distinguished to identify the statin-induced mitochondrial dysfunction.

03

Conditions studied

  • Arterial Occlusive Diseases

Keywords

  • Peripheral Arterial Occlusive Disease (PAOD)
  • Phosphorus-31
  • Magnetic Resonance Imaging (MRI)
  • Spectroscopy
  • Revascularization
  • Claudication with surgical planning
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patient with Peripheral arterial occlusive disease with claudication and surgery planning

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Peripheral arterial occlusive disease (PAOD) with claudication and surgery planning with proximal lesion (iliac or femoral (x-ray angiography or CT or MRA) and no distal lesions (doppler)
  • ABI\<0.90 or >1.30
  • signed consent form
  • health insurance coverage

Exclusion criteria

Exclusion Criteria:

  • in the practice of MRI: pacemaker, metallic cardiac valve, intra-ocular metal part, claustrophobia
  • critical ischemia >15 days
  • Type 1 or 2 diabetes
  • weight >200kg
  • non stabilized hypertension
  • beta-blockers
  • non-atherosclerotic vascular occlusive disease (Buerger disease, Takayasu disease, venous disease, trapped popliteal artery etc..)
  • Neurological pathology/non-voluntary contraction
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
40 participants (estimated)
Patient registry
No

Groups and cohorts

  • PAOD patients statin (+)

    Patients with Peripheral Arterial Occlusive Disease (PAOD) and statin treatment. They will have Magnetic Resonance Imaging (MRI; muscular volume and composition) and gated-P-31 magnetic resonance spectroscopy (MRS) with low-intensity ergometric exercise. It will be performed before surgery (within 48h) and after surgery (first week)

    Device: Magnetic Resonance Imaging (MRI)

  • PAOD patients statin (-)

    Patients with Peripheral Arterial Occlusive Disease (PAOD) without statin treatment . They will have Magnetic Resonance Imaging (MRI ; muscular volume and composition) and gated-P-31 magnetic resonance spectroscopy (MRS) with low-intensity ergometric exercise. It will be performed before surgery (within 48h) and after surgery (first week)

    Device: Magnetic Resonance Imaging (MRI)

Interventions

  • DeviceMagnetic Resonance Imaging (MRI)

    MRI (muscular volume and composition) and gated-P-31 magnetic resonance spectroscopy (MRS) with low-intensity ergometric exercise.

06

What researchers measure

Primary outcomes

  1. Muscle phosphocreatine (PCr) recovery time constant

    Muscle phosphocreatine (PCr) recovery time constant (index of muscle aerobic capacity) after gated low-intensity exercise (2"maximum voluntary isometric dorsiflexion contractions, at 30s intervals for 8min (total contractions = 15)

    Time frame: During the MRI procedure

Secondary outcomes

  1. Muscular volume and content

    impact of muscular volume and content. Measures will be extracted from DIXON and T2\* MRI

    Time frame: During the MRI procedure

  2. PCr recovery time constant

    impact of statin treatment on PCr recovery time constant

    Time frame: During the MRI procedure

07

Study locations

1 of 1 sites recruiting
  • Chu Saint-Etienne
    Saint-Étienne, France
    Recruiting
    • Pierre CROISILLE, PhD · Principal investigator
    • Jean-Noël ALBERTINI, PhD · Sub investigator
    • Jean-Pierre FAVRE, PhD · Sub investigator
    • Mourad BOUFI, PhD · Sub investigator
    • Aude GROGNET, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2019 (actual). Primary completion is estimated for Apr 2025, 74 months after the start.

Of 23 observational studies under Arterial Occlusive Diseases, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 50. This study's planned 74 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2018
First posted
Oct 29, 2018
StartActual
Feb 13, 2019
Primary completionEst.
Apr 2025
CompletionEst.
Apr 2025
Last update
Apr 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03723473
Collaborators
Dr MAYER Ronald A. Department of Physiology, Michigan State University, Dr SLADE Jill M. Department of Osteopathic Manipulative Medicine, Michigan State University
Responsible party
Sponsor
First posted
Oct 29, 2018
Start date
Feb 13, 2019
Primary completion
Apr 2025 (estimated)
Completion
Apr 2025 (estimated)
Last update
Apr 25, 2024

Study contacts

Pierre CROISILLE, PhD
Contact
croisille@creatis.insa-lyon.fr
(0)477127584 ext. +33
Pierre CROISILLE, PhD
principal investigator · CHU SAINT-ETIENNE

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion